Neurofibromatosis type I and migraine in childhood: a new therapeutic perspective

"Introduction Neurofibromatosis type 1 (NF1) is a rare genetic disease, associated. with many neurological comorbidities, such as headache. Despite the. high prevalence of headache in this population, little data exists regarding the. classification of headaches experienced by patients with NF1.. Objective Aim of the study was to verify the efficacy and safety of nutraceutical. complex containing Ginkgolide B\/Coenzyme Q10\/Riboflavin\/Magnesium. for the prophylaxis in a sample of children affected by NF1 presenting migraine. without aura symptoms.. Methods Ginkgolide B\/Coenzyme Q10\/Riboflavin\/Magnesium complex was. orally administered as prophylactic therapy twice a day for 6 months to 18. school-aged patients affected by NF1 and presenting symptoms of migraine. without aura (MoA) (10 M; mean age: 8.4±1.65). Each patient kept a journal. to record: number, intensity (according to VAS scale), duration of attacks and. concomitant symptoms. In addition, the Ped-MIDAS scale was administered. to assess migraine-related disability. To verify the efficacy of the association,. we tested the starting frequency (T0) of headache after 6 months (T1) and. then we calculated the migraine frequency delta percentage to express the decrease. in monthly frequency.. Results A reduction (p<0.001) in all migraine outcomes (frequency, duration,. intensity and disability grade) was reported after the period of treatment. [1].. Discussion and conclusions Nutraceutical complex containing Ginkgolide. B\/Coenzyme Q10\/Riboflavin\/Magnesium for the prophylaxis of migraine. also in NF1 subjects, pinpointing the importance of considering the migraine. symptomatology as the therapeutic target and not the basic pathology as impediment. for a correct management."